Suppository formulations as a potential treatment for nephropathic cystinosis.
Buchan, Barbara; Kay, Graeme; Matthews, Kerr H.; Cairns, Donald
Kerr H. Matthews
Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of all the organs. It is treated by the 6-h oral administration of the aminothiol, cysteamine, which has an offensive taste and smell. In an attempt to reduce this frequency and improve the treatment, cysteamine-containing polyethylene glycol suppositories were prepared and evaluated for dissolution and stability. The results demonstrated that cysteamine release was complete after 30 min, and that there was a uniform drug distribution within the formulations. Twelve-month stability tests highlighted a potential incompatibility among some excipients, although stability was demonstrated for the cysteamine suppositories up to 6 months. These suppositories may provide a useful alternative to the current oral therapy for cystinosis.
|Journal Article Type||Article|
|Publication Date||Oct 31, 2012|
|Journal||Journal of pharmaceutical sciences|
|Peer Reviewed||Peer Reviewed|
|Institution Citation||BUCHAN, B., KAY, G., MATTHEWS, K.H. and CAIRNS, D. 2012. Suppository formulations as a potential treatment for nephropathic cystinosis. Journal of pharmaceutical sciences [online], 101(10), pages 3729-2738. Available from: https://doi.org/10.1002/jps.23246|
|Keywords||Cystinosis; Formulation; PEG; Physical stability; Dissolution; Thermal analysis; Paediatric|
BUCHAN 2012 Suppository formulations as a potential
You might also like
Novel vanillin derivatives: synthesis, anti-oxidant, DNA and cellular protection properties.